Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

US FDA, PTO Pulled Into Debate Over Patents And Drug Pricing

Executive Summary

Senator Tillis requests the two agencies conduct an independent analysis of I-MAK data and the ‘false narrative’ that patents are to blame for high drug prices.

You may also be interested in...



US Senators Urge PTO’s Vidal To Tackle Pharma Patent Thickets

A bipartisan group of senators has written to the US Patent and Trademark Office, urging it to tackle the impact of patent thickets on the generic and biosimilar drug industries.

FDA, USPTO In Middle Of Congressional Tug-Of-War Over Patents And Drug Pricing

Senators Hassan and Cassidy contend the lack of coordination between the two agencies may allow patent thickets to grow. Meanwhile, Sen. Tillis is pushing the agency to refute data alleging patents are to blame for high drug prices.

I-MAK Defends ‘Patent Thicket’ Claims In Response To Thom Tillis Letter

The Initiative for Medicines, Access & Knowledge has responded to criticisms leveled by North Carolina senator Thom Tillis at a report it published in 2018. The report accuses pharmaceutical firms of using patent thickets to suppress generic and biosimilar competition in the US market.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

PS145654

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel